Roche NimbleGen Announces Frank Pitzer as New CEO
News Mar 26, 2010
Roche NimbleGen has announced that Frank Pitzer has been appointed as CEO. Dr. Pitzer’s extensive background and experience of over eight years at Roche will be instrumental in guiding the company through its next stage of growth.
With his successful track record in several key management positions within Roche Diagnostics, he brings a wealth of organizational, commercial, and relevant operating experience in key areas impacting the genomics and life science industry.
Dr. Pitzer most recently served as Head of Divisional Quality and Regulatory Affairs reporting directly to the CEO of Roche Diagnostics and was also an active member of the Diagnostics Executive Committee (DEC). In addition to his extensive management experience and background at Roche, Dr. Pitzer brings a broad scientific perspective having earned a PhD in Biology from Max Planck Institute for Biochemistry.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.